ProcureCon Pharma US 2017

October 24-October 26, 2017

Westin Philadelphia, PA

Contact Us: 1.888.482.6012

Day 1: ProCurious The Visionaries - Elevating The Standards For Medicine’s Life-Changing Mission

07:15 AM - 08:15 AM Continental Breakfast & Registration

08:15 AM - 08:25 AM Welcome Remarks & Ice Breaker (Learn Different Category Perspectives)

Jenna Williams, Program Director, ProcureCon Pharma


Jenna Williams

Program Director
ProcureCon Pharma

08:25 AM - 08:35 AM Chairperson’s Opening Remarks

08:35 AM - 09:00 AM Keynote: Developing And Executing Corporate Strategy: Influential Opportunities Created Through Procurement’s Transformation Role-Playing

Ron Perry, Vice President, Global Procurement , Pfizer Global Supply & Global Operations


Ron Perry

Vice President, Global Procurement
Pfizer Global Supply & Global Operations

09:00 AM - 10:00 AM Multiple Perspective Case Study: Overcoming Global Silos To Keep Procurement Strategy Strong Across The World

Dapo Ajayi , Chief Procurement Officer, AstraZeneca Ed McAndrews, Head of Procurement, North America, AstraZeneca Sean Cumbie, Head of Procurement & Global Biotech, AstraZeneca


Dapo Ajayi

Chief Procurement Officer

Ed McAndrews

Head of Procurement, North America

Sean Cumbie

Head of Procurement & Global Biotech

10:00 AM - 10:40 AM Case Study Interactive: Procurement’s Transformation In Driving Enterprise Wide Value

Ahmet Karacaoglu, Executive Director, Head of Global Strategic Sourcing, Alexion
As a CPO surveys the supply chain view, aligning leadership objectives into actionable procurement insight internationally prioritizes the allocating of attention to procurement transformation needs and the access to shared resources that can help speed drugs to market. Unite with your colleagues to implement how you can relay strategic plans to equip indirect and direct teams with the necessary tools for successful execution of both categories regionally & globally. An analytical look at Alexion’s:

• 4 Pillars of procurement value & metrics
• Gap analysis – technology, people, and process
• EC alignment
• Integrating procurement with critical functional partners and the supply chain to make optimal enterprise decisions
• Cultivating an enterprise-wide collaboration to ensure VBS & seamless operations throughout the product lifecycle
• Project pipeline prioritization, health and resource management
• Derive a sustainable R&D procurement ecosystem for additional value creation


Ahmet Karacaoglu

Executive Director, Head of Global Strategic Sourcing

10:40 AM - 11:20 AM Networking Break In The Solutions Zone

A lot to take in for our high intensity executive sessions. As you take a break, digest all of the activity that took place and enjoy the refreshments, feel free to connect with our speakers and solution providers as you consider how to amalgamate the procurement mindset for your organization in new age pharma and where each practitioner can activate collaboration & proficiency within your organization.

11:20 AM - 11:45 AM Case Study Interactive: The Technological Revolution and Modernizing Business Partnering

Chad Friesz, Head of Procurement, US Business Unit, Oncology & Vaccines, Takeda
Discover Takeda sets the foundation, builds people skills, and embraces technology to evolve Procurement’s ability to match the business need and pace, delivering sustained value. Gain a further understanding behind the value proposition of:

Modernizing Business Partnering
Evolving the approach to build solid, trust-based partnerships where Procurement has a seat at the table from day one
Helping to understand and align the various business strategies with the corporate mission. This starts with capturing the mind-set of the Procurement organization, extending to the business through vision, training, and consistent messaging.
Procurement’s Digital strategy and focusing on what really matters
View insight and efficiency through a digital lens to help to drive a more efficient and modern approach to Procurement.


Chad Friesz

Head of Procurement, US Business Unit, Oncology & Vaccines

11:45 AM - 12:05 PM Keynote Presented By Scientist

This is a very exciting time in pharma procurement where global trends show CPOs are reshaping their roles in the C-suite. The modern procurement division has a direct impact on the growth of their companies that goes beyond cost control to become a part of the whole organizational innovation process.
Insert yourself into a deep dive of how the CPO ensures early involvement of Procurement and drives alignment with leaders to provide collaboration of Pharma’s internal operations. Aim to assess how to:

Cleverly galvanize support from your stakeholders and ensure an increasingly integral role in strategic decision making
What nuances can a CPO introduce to innovate within procurement or use procurement as an influencer to enable business innovation
Does procurement’s reporting structure need to change: Setting precedence for cross-functional engagement
Improving connections with stakeholders to locate untapped sources of value
Specifically getting your foot in the door with marketing and venture capitalist stake holders
How will a CPO be meeting the needs of the industry in 2030?


Marcelo B. Cunha Loureiro

Head of Procurement for Americas

Joe Shatynski

Head of Strategic Business Services: Senior Director
Daiichi Sankyo Inc.

Tanya Momtahen

Vice President & Head of Global Procurement, Scientific & Clinical,

Thomas Cho

Head of Corporate Procurement: Director,

Michelle Charpentier

Senior Director Source To Pay, Head of Indirect Procurement

12:45 PM - 1:45 PM Lunch

Track A: Digitization & Risk Mitigation For Indirect Categories

1:45 PM - 2:25 PM Case Study Interactive: Cultivating An Enterprise-Wide Collaboration To Ensure Seamless Operations: Value Beyond Savings (VBS), Innovation, And Environmental Sustainability

Akbar Alinani, Director of Global Procurement, Bristol-Myers Squibb
In the race for speed to patient, eliminating obstacles and charting a clear path forward is critical in the Research & Development function. Having a strategic partnership with Procurement allows business partners to focus on what matters most – the science. By improving and enhancing lab operations, scientists at Bristol-Myers Squibb are able to quickly retrieve the assets they need as they need them, all while driving sustainable lab practices. Procurement expert Akbar Alinani details his important relationship with his stakeholders and innovative supply chain strategy, focusing on:
End-to-End Supply Chain Transformation focusing on sustainability and environmental footprint reduction
Proactive sourcing strategy to develop long-term, critical partnerships with suppliers
Driving value beyond savings through RFID technology deployment and innovation
Derive a sustainable R&D procurement ecosystem for productivity and continuous improvement


Akbar Alinani

Director of Global Procurement
Bristol-Myers Squibb

Track B: Digitization & Risk Mitigation For Direct/ Manufacturing Categories

1:45 PM - 2:25 PM Synergy Workshop: Direct & Manufacturing Collaboration On Serialization Implementation & Packaging Assurance

Global counterfeit drug market ranges from $75 to $200 billion and can make up half of all drugs sold in some low-income countries. With the dangers associated to this unfair competition, counterfeits ultimately raise the price of medicines by requiring legitimate manufacturers to use considerable resources to ensure a safe supply chain for genuine pharmaceuticals. Considering existing government policies and enforcement efforts are often insufficient to address these problems, collaborate to discuss how best to address inconsistencies in solution procurement through serialization and the regulated SRM.

Track C: Brain Storm BoardRoom Session: Call To Action For A Unified Procurement Function

1:45 PM - 2:25 PM Crystal Ball Gazing For Biotechs

Ahmet Karacaoglu, Executive Director, Head of Global Strategic Sourcing, Alexion
Those in this group will be collaborating around their biotech strategies of addressing pain points and proficiency in overall procurement development. Areas to gain insight into are:
• End Goal: Independent Growth or M&A
• Writing contracts with exit clauses in the event of an acquisition.
• Spend Focus: Total Cost; Consolidation; Compliance, Commercialization


Ahmet Karacaoglu

Executive Director, Head of Global Strategic Sourcing

Track A

2:25 PM - 2:45 PM Tealbook Case Study: Transforming Your Supplier Engagement Model with AI: Actionable Intelligence

Michelle Charpentier, Senior Director Source To Pay, Head of Indirect Procurement, BioMarin Dana Small, Sourcing Manager, BioMarin Pharmaceutical
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.
Session attendees will hear about:
1.The actionable value of increasing procurement’s visibility into current preferred suppliers and trusted intelligence about other potential supplier partners
2.The benefits of providing the business with instant access to credible supplier information, allowing them to participate directly in early discovery efforts
3.The advantage of increasing BioMarin’s share of knowledge and building a legacy of intelligence that will offer sustained returns
4.Ensuring alignment between the long term strategic vision and immediate supporting tactics of supplier intelligence


Michelle Charpentier

Senior Director Source To Pay, Head of Indirect Procurement

Dana Small

Sourcing Manager
BioMarin Pharmaceutical

Track B

2:25 PM - 2:45 PM CoreTrust Case Study

Track A

2:45 PM - 3:10 PM Case Study: The Trials & Successes Medimmune’s Internal Innovation: A Journey Through E-Procurement Cross Functionality

Mark Davis, Director – MedImmune Procurement Business Partner,, AstraZeneca
AstraZeneca has partnered with Medimunne on an eProcurement platform that has recently launched in MedImmune research. This platform is an enabling tool that has integrated globally distributed strategic procurement to manage MedImmune’s large molecule services outsourcing across a spectrum of categories: pre-clinical services, toxicology, specialty laboratory development and testing, biomarker services, etc.
Utilizing the platform, Medimmune is on track to go from near zero spend under management, to roughly 80% under management in less than 6-months, while cutting engagement time by 50%. Additionally, the solution they have built integrates information taken from decisions made at the exploratory stage and makes them available to Clinical teams globally to quickly move forward with trial engagements. Through their journey, take on how to:

Assess your product lifecycle and how procurement’s needs within
Standardize and streamline the way data is captured, stored and management, to enable integration and cross-analysis
Address data duplication
Scale up your internal resources for gaining endorsement from Stakeholders


Mark Davis

Director – MedImmune Procurement Business Partner,

Track B

2:45 PM - 3:10 PM Case Study: “Enabler Of Process” To “Agent Of Change”-Unlock The Missing Links Between Market Intelligence, Data Convergence & Business Value

Samuel Friedman , Director of Sourcing Excellence: Global Manufacturing & Supply, Bristol-Myers Squibb
As Pharma have amassed large amounts of data over the years, the challenges associated with categorizing data and making it meaningful has also grown for procurement and its ability to capture market intelligence. to With big data at the forefront, take a deeper look at how to proficiently speed drug delivery to the market with assess to comprehensively accurate information. Immerse yourself in:

How AI helps leverage big data and converts it into B.I.
What your technology platform can do for you and are there any tools that can talk to your current systems
What data you will need, where it will live, and how you will access it
Establishing the process to ensure actionable data and its protection.
What the key features are that will drive user adoption & the necessary training to support Digitization’s changes to procurement’s


Samuel Friedman

Director of Sourcing Excellence: Global Manufacturing & Supply
Bristol-Myers Squibb

Track C

2:45 PM - 3:10 PM The Generic Generation

Generic Pharma invites a discussion regarding the impacts of future healthcare and the sourcing processes that keep them competitive to their bioequivalent brand products. Ask yourself, how will the business models and investment cycles change with the blurring of more biosimilars entering the market?

Track C

3:10 PM - 3:50 PM Networking Break In The Solutions Zone

Track C

3:50 PM - 4:50 PM Interactive Roundtable Discussions

After a busy day of active listening, keynotes and networking, take control of your own event experience. This is your opportunity to network with industry peers with very similar challenges, interests and responsibilities as you discuss strategies for risk management from regional to global proactivity. We invite you to provide your insight as each roundtable is facilitated by a subject matter expert. After 30 minutes, you will be able to choose a second topic to participate in.

Table 1: Dot The Is And Cross The Ts; Remaining Vigilant In Procurement Compliance
Table 2: Aligning Your Sources: Internal & External Collaboration
Table 3: Marketing: Advancing Promoters To Protectors: Creating VanGuards Of Consumer Compliance

Table 4: Optimizing the Use of Your Lab Equipment Assets

Table 5: Best Practices in Developing and Maintaining an Effective Clinical Outsourcing Strategy

Table 6: Avoiding The “Damage Done With Data Tampering”
Table 7: Influencing Business Connectivity Through Digitisation

Table 8: How Can Benchmarking Really Inspire You To Be Better?

Table 9: Working With Suppliers In Untapped Solution Markets

Track A: Risk Management & Compliance For Indirect

4:50 PM - 5:30 PM Synergy Workshop: The Billion Dollar Brainstorm: From Strategy to Actions Plan -What Does the Future of R&D Procurement Behold?

Ratan Ratnesh, Director & Head of Clinical Outsourcing, Otsuka
This 40 minute interactive-brainstorm-session will split audience into groups to discuss the above topics in rotation for 10mins. At the end of each topic’s brainstorming, the group will need to come up with one top-tip considered for implementation that will be shared at the end of this session.

1. Organizational chart and structure: Where should R&D procurement team fit compared with other outsourcing and contract management teams? Most importantly, how does procurement contract for ‘patient insights in approaching the patient and consideration of various needs, ie. informed consent, IRB approvals

2. How can R&D procurement collaborate from discovery to clinical? How does procurement contract for ‘patient insights in approaching the patient and consideration of various needs, ie. informed consent, IRB approvals. The current challenges and solutions?

3. The vision: Implementing S2P and real time data analytics for strategic sourcing intelligence (extracting long tail enterprise data and the future of analytics looking a lot like Google)- Can the impacts complicate or elevate R&D innovation? Where would the complications lie?


Ratan Ratnesh

Director & Head of Clinical Outsourcing

Track B: Risk Management & Compliance For Direct & Manufacturing

4:50 PM - 5:30 PM Case Study Interactive: Partnering With R&D And Manufacturing To Define SRM Strategy & Process

Find out how to bring about synergies from cross functional teams that collaborate well. Teamwork between Sourcing, R&D and the CRO, is essential for demonstrating the validity of the model as executed with CROs and CMOs.


·How stability studies are carried out to assess the variation in quality over time of a drug substance and finished product under the influence of numerous environmental conditions.

·Introducing a ‘should-cost’ model to calculate the cost of performing analytical tests and captures cost efficiency when pooling coherent pull points in any given stability study.

·How a collaborative approach by sourcing managers, scientists and CROs can lead to studies that ensure steps towards analysis coincide.

·How to engage CMOs/CROs in multi-area analysis thus creating a powerful negotiation

Brainstorm Board Room Sessions

4:50 PM - 5:30 PM Presentation: Mitigating 3rd Party Risk: Bringing The Outside In

Andrew Shigo, Global Head, Strategy Realization and Procurement Operations, Roche Pharmaceuticals
It's hard to put a cost on risk - but mitigating it is nothing short of priceless, and needs to be incorporated into the value equation. So how do you know if your new vendor has the right programs, controls, metrics, and data controls in place? Will they steal customer data? Do they have the right back up systems? And what risk do you need to apply to what suppliers? In this invaluable presentation, learn the latest techniques for vetting suppliers.

Andrew Shigo

Global Head, Strategy Realization and Procurement Operations
Roche Pharmaceuticals

Track A: Risk Management & Compliance For Indirect

5:30 PM - 6:10 PM “Preparing For The Worst” Workshop: Leadership In The Face of Major Supply Chain Disruptions: Differentiating Between Baseline And Contextual Traits

Arash Azadegan, Associate Professor of Supply Chain Management, Rutgers Business School Iana Shaheen, Ph.D. Candidate, University of South Florida
Most of Pharma knows that a third-party incident can cost them dearly, but few realize just by how much. In terms of downside losses, there are several ways in which companies can incur unnecessary expenses, expose themselves to fines, or be held responsible for restitution, not to mention the opportunity costs associated with not being able to serve existing customers or to pursue new business in the wake of a disruptive event. However, one of the more prominent and more costly risks associated with third parties is regulatory non-compliance. This pressure is unlikely to ease anytime soon since regulatory scrutiny and associated life and industry endangerment are intensifying ramifications in the Pharma and Biotech world. Voice your leadership endorsement when analyzing supply chain disruption and see how you can:

  • Identify what leadership characteristics help companies better respond to supply chain disruptions
  • Clarify whether leadership effectiveness changes during the life-cycle of a supply chain disruption
  • Differentiate response and recovery approaches to different types of disruptions
  • Ultimate goals: business continuity and resiliency


Arash Azadegan

Associate Professor of Supply Chain Management
Rutgers Business School

Iana Shaheen

Ph.D. Candidate
University of South Florida

Track B: Risk Management & Compliance For Direct & Manufacturing

5:30 PM - 6:10 PM Case Study: Successful Defense: Proposed Regulatory Starting Materials Changing The Game On Marketing Applications Worldwide

Valdas Jurkauskas, Senior Director of Pharmaceutical Development, Manufacturing & Quality, Corbus Pharmaceuticals
Money, quality and time are the key factors in pharmaceutical development. In reality, time controls quality: if given enough time, robust processes will be developed; quality controls the cost, robust processes will yield reproducibly high quality products. The emphasis throughout clinical development stages is on finished goods, however regulatory starting materials do not receive the same level of attention. Furthering the problem, a sponsor is quick to assume that starting materials designation used throughout clinical trial applications will be accepted in the marketing application.

Serving as critical quality attributes assessment:

  • Assess EMA critical steps for covering a broad spectrum of manufacturing processes
  • Identify the higher risk of (EMA/FDA) agencies not accepting proposed starting materials designation
  • Consider the turning points of requiring to extend GMP process upstream and how agencies view regulatory starting materials in the marketing application
  • Understand the impact of regulatory agencies agreement on starting materials designation and the risks associated with supply chain invalidation and the impact of regulatory agencies agreement on starting materials designation:
  • How do you recover from delay in approval when converting proposed starting materials into GMP process intermediates


Valdas Jurkauskas

Senior Director of Pharmaceutical Development, Manufacturing & Quality
Corbus Pharmaceuticals

Brainstorm Board Room Sessions

5:30 PM - 6:10 PM The Big Debate: Who Really Owns Intellectual Property

Anthony Emma, Associate Director of Procurement Operations, Novo Nordisk
In today’s pharmaceutical sector, speed is the name of the game. Pharmaceutical companies rely on the sanctity of patents to protect their intellectual property and provide them the market advantage needed for pricing power, traditionally derived from this exclusivity. When agencies develop proprietary licenses for the organization, how can a company protect itself from any lawsuits that arise from the growth of patent trolls? Express your views on who really owns the intellectual property and how the contract management process should be discussed: Considered in the debate

• How intellectual property and innovation ownership are vital to a company’s marketing campaign
• How should contracts be put in place to minimize litigation indemnification for the use of proprietary technology
• How much is an agency responsible for sharing the risk
• Costs associated with indemnification clauses, and who should pay what


Anthony Emma

Associate Director of Procurement Operations
Novo Nordisk

6:10 PM - 7:40 PM Procurement Practitioners Meet & Greet

Join your fellow practitioners for a relaxing cocktail hour and plenty of hand shakes to kick off our 2017 event!”
**Practitioners Only**

Live Chat Software